Report Overview
Alfuzosin is a selective alpha-1 adrenergic receptor antagonist, primarily used in the treatment of benign prostatic hyperplasia (BPH). BPH is a non-cancerous enlargement of the prostate gland that commonly affects older men, causing lower urinary tract symptoms (LUTS) such as difficulty in urination, increased frequency, and incomplete bladder emptying.
Alfuzosin works by relaxing the muscles in the prostate and bladder neck, facilitating easier urine flow. As a nonselective alpha-blocker, Alfuzosin provides symptomatic relief without significantly impacting blood pressure, making it a preferred treatment for patients who are intolerant to other alpha-blockers.
Available in 2.5mg and 10mg formulations, Alfuzosin is often prescribed in extended-release tablet forms and is widely available through hospitals, pharmacies, and drug stores globally. With a growing aging population and increased awareness around men’s health issues, the global demand for Alfuzosin is witnessing consistent growth, making it a significant segment within the pharmaceutical sector focused on urological disorders.
Market Analysis
The global Alfuzosin Market was valued at USD 693.2 million in 2024 and is projected to reach USD 946.2 million by 2032.
Growing at a Compound Annual Growth Rate (CAGR) of 4% during the forecast period of 2025 to 2032.
This growth trajectory reflects a strong demand for effective therapeutics to treat BPH and associated urinary symptoms.
